Core Viewpoint - Tectonic Therapeutic, Inc. has appointed François Nader, M.D., MBA, as an independent director and Chair of the Board, effective April 1, 2026, marking a significant leadership transition within the company [1][2][3]. Group 1: Leadership Changes - François Nader will assume the role of Chair of the Board, succeeding Terry McGuire, who will remain on the Board until the 2026 Annual Meeting of Stockholders, anticipated in June 2026 [2]. - Terry McGuire expressed support for Dr. Nader's appointment, highlighting the importance of this transition as Tectonic evolves to its next growth stage [3]. Group 2: Dr. Nader's Background - Dr. Nader brings over 30 years of experience in the biotechnology and pharmaceutical industry, currently serving as an Independent Director of Moderna, Inc. [2]. - His previous roles include Chairman and Executive Chairman of various biotechnology companies, leading to significant strategic transactions, including acquisitions by major pharmaceutical firms [2][3]. Group 3: Company Overview - Tectonic Therapeutic focuses on the discovery and development of therapeutic proteins and antibodies that modulate G-protein coupled receptors (GPCRs) [1][4]. - The company utilizes its proprietary technology platform, GEODe™, to develop biologic medicines aimed at addressing significant unmet medical needs [4].

Table of Contents As filed with the Securities and Exchange Commission on July 19, 2024 Registration No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-1 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Tectonic Therapeutic, Inc. (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organization) (Primary Standard Industrial Classification Code No.) Delaware 2836 81-0710585 (I.R.S. Employer Identification Number) 4 ...